Intervention

standard chemotherapy

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common conditions3

Lead sponsors shown3

Clinical trials

3 shown

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast CancerNCT07162051 · 2023-03-03

COMPLETED

Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung CancerNCT04263051 · 2020-09-09

COMPLETED

Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast CancerNCT02483767 · 2015-06-01

COMPLETED

Common conditions

Advanced Non-small Cell Lung Cancer1 Breast Cancer1 HR+/HER2- Early Breast Cancer1

Leading sponsors

Centre Hospitalier Universitaire de Besancon 1 Peking Union Medical College Hospital 1 Xijing Hospital 1

Trial status mix

COMPLETED3

Phase mix

PHASE22

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.